更多内容请点击

中国全科医学

• •

射血分数保留性心力衰竭的药物治疗进展

王艺衡1, 2，许晓明2*，夏云龙2，夏林莺3，韩雪2，郭永珍2,4，刘泉池2，闫文俊2   

  1. 1.710032 陕西省西安市 空军军医大学基础医学院学员二大队；2.710032 陕西省西安市 空军军医大学第一附属医院（西京医院）心血管内科；3.710004 陕西省西安市 西安交通大学第二附属医院心血管内科；4.710127 陕西省西安市 西北大学公共管理学院
  • 收稿日期:2024-10-21 修回日期:2024-11-28 接受日期:2024-12-17
  • 通讯作者: 许晓明

  1. 1.The Second Brigade of Cadet, Basic medical research academy, Fourth Military Medical University, Xi’an 710032, China；2.Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, China；3.Department of Cardiology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, China；4.School of Public Management, Northwest University, Xi'an 710127, China
  • Received:2024-10-21 Revised:2024-11-28 Accepted:2024-12-17
分享到

摘要： 射血分数保留的心力衰竭（HFpEF）是一种病理生理机制复杂的系统性疾病，占所有心衰类型50%以上，5年死亡率高达50%-75%，危害极大。HFpEF具有极强的异质性，病因、病理生理机制及临床表现多种多样，治疗困难。尽管如此，近年来HFpEF治疗仍取得了很大的进步，部分药物已被证实可改善HFpEF患者生活质量，减少不良事件的发生。本文基于HFpEF独特的病理生理机制，对HFpEF相关药物治疗的最新临床证据进行综述，旨在为HFpEF的综合治疗提供理论基础和实践指导。

关键词: 射血分数保留的心力衰竭, 病理生理, 异质性, 药物治疗, 综述

Abstract: Heart failure with preserved ejection fraction (HFpEF) is a systemic condition characterized by complex pathophysiological mechanisms, affecting over 50% of all heart failure patients, with a five-year mortality rate ranging from 50% to 75%. HFpEF is highly heterogeneous, with diverse etiologies, pathophysiological mechanisms, and clinical manifestations, all of which complicate its management and treatment. Despite these present challenges, significant progresses have been made in the management of HFpEF in recent years. Certain medications have been shown to improve quality of life and reduce the risk of adverse events in HFpEF patients. This article provides a review of the latest clinical evidence on pharmacological treatments for HFpEF, focusing on the disease’s unique pathophysiological mechanisms, thereby offering a solid theoretical foundation and practical guidance for its management.

Key words: Heart failure with preserved ejection fraction, Pathophysiology, Heterogeneous, Pharmacotherapy, Review

冀ICP备12018774号-6　冀公网安备 13040302001295号　网站版权 © 《中国全科医学》编辑部　技术支持：北京玛格泰克科技发展有限公司